CA2342341A1 - Nouvelle composition - Google Patents
Nouvelle composition Download PDFInfo
- Publication number
- CA2342341A1 CA2342341A1 CA002342341A CA2342341A CA2342341A1 CA 2342341 A1 CA2342341 A1 CA 2342341A1 CA 002342341 A CA002342341 A CA 002342341A CA 2342341 A CA2342341 A CA 2342341A CA 2342341 A1 CA2342341 A1 CA 2342341A1
- Authority
- CA
- Canada
- Prior art keywords
- treatment
- component
- pharmaceutical formulation
- composition
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
L'invention concerne une composition constituée d'un premier constituant (a), un monohydrate de R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyrane-5-carboxamide hydrogène (2R, 3R)-tartrate, et d'un deuxième constituant (b), de la paroxétine sous forme de base libre, ou un sel et/ou un solvate pharmaceutiquement acceptable(s) de celle-ci; la préparation de cette composition; des formulations pharmaceutiques contenant ladite composition; une méthode de traitement de troubles affectifs tels que des troubles de l'humeur et des troubles anxieux à l'aide de ladite composition, et l'utilisation de ladite méthode de traitement; et une trousse contenant ladite composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9803156A SE9803156D0 (sv) | 1998-09-16 | 1998-09-16 | A new composition |
| SE9803156-0 | 1998-09-16 | ||
| PCT/SE1999/001597 WO2000015218A1 (fr) | 1998-09-16 | 1999-09-13 | Nouvelle composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2342341A1 true CA2342341A1 (fr) | 2000-03-23 |
Family
ID=20412627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002342341A Abandoned CA2342341A1 (fr) | 1998-09-16 | 1999-09-13 | Nouvelle composition |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1128825A1 (fr) |
| JP (1) | JP2002524508A (fr) |
| KR (1) | KR20010099647A (fr) |
| CN (1) | CN1317964A (fr) |
| AR (1) | AR021808A1 (fr) |
| AU (1) | AU6378099A (fr) |
| BR (1) | BR9913748A (fr) |
| CA (1) | CA2342341A1 (fr) |
| CZ (1) | CZ2001961A3 (fr) |
| EE (1) | EE200100157A (fr) |
| HU (1) | HUP0103544A3 (fr) |
| ID (1) | ID28785A (fr) |
| IL (1) | IL141519A0 (fr) |
| IS (1) | IS5879A (fr) |
| NO (1) | NO20011312L (fr) |
| PL (1) | PL346763A1 (fr) |
| SE (1) | SE9803156D0 (fr) |
| SK (1) | SK3262001A3 (fr) |
| TR (1) | TR200100779T2 (fr) |
| WO (1) | WO2000015218A1 (fr) |
| ZA (1) | ZA200101946B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2269467T3 (es) | 2000-10-13 | 2007-04-01 | Neurosearch A/S | Tratamiento de transtornos afectivos por la accion combinada de un agonista del receptor nicotinico y una sustancia monoaminergenica. |
| WO2006093192A1 (fr) * | 2005-03-04 | 2006-09-08 | Tokyo Medical And Dental University | Agent therapeutique de prevention de la recurrence d’une psychose ou d’une schizophrenie induite par psychostimulant |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
-
1998
- 1998-09-16 SE SE9803156A patent/SE9803156D0/xx unknown
-
1999
- 1999-09-13 ID IDW20010581A patent/ID28785A/id unknown
- 1999-09-13 EE EEP200100157A patent/EE200100157A/xx unknown
- 1999-09-13 JP JP2000569802A patent/JP2002524508A/ja active Pending
- 1999-09-13 SK SK326-2001A patent/SK3262001A3/sk unknown
- 1999-09-13 IL IL14151999A patent/IL141519A0/xx unknown
- 1999-09-13 CZ CZ2001961A patent/CZ2001961A3/cs unknown
- 1999-09-13 AU AU63780/99A patent/AU6378099A/en not_active Abandoned
- 1999-09-13 EP EP99951319A patent/EP1128825A1/fr not_active Withdrawn
- 1999-09-13 CN CN99811010A patent/CN1317964A/zh active Pending
- 1999-09-13 KR KR1020017003337A patent/KR20010099647A/ko not_active Application Discontinuation
- 1999-09-13 CA CA002342341A patent/CA2342341A1/fr not_active Abandoned
- 1999-09-13 HU HU0103544A patent/HUP0103544A3/hu unknown
- 1999-09-13 PL PL99346763A patent/PL346763A1/xx unknown
- 1999-09-13 BR BR9913748-8A patent/BR9913748A/pt not_active Application Discontinuation
- 1999-09-13 WO PCT/SE1999/001597 patent/WO2000015218A1/fr not_active Application Discontinuation
- 1999-09-13 TR TR2001/00779T patent/TR200100779T2/xx unknown
- 1999-09-15 AR ARP990104626A patent/AR021808A1/es not_active Application Discontinuation
-
2001
- 2001-03-07 IS IS5879A patent/IS5879A/is unknown
- 2001-03-08 ZA ZA200101946A patent/ZA200101946B/en unknown
- 2001-03-15 NO NO20011312A patent/NO20011312L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EE200100157A (et) | 2002-08-15 |
| HUP0103544A2 (hu) | 2002-05-29 |
| PL346763A1 (en) | 2002-02-25 |
| SK3262001A3 (en) | 2001-08-06 |
| JP2002524508A (ja) | 2002-08-06 |
| EP1128825A1 (fr) | 2001-09-05 |
| BR9913748A (pt) | 2001-07-10 |
| CN1317964A (zh) | 2001-10-17 |
| AU6378099A (en) | 2000-04-03 |
| TR200100779T2 (tr) | 2001-10-22 |
| IL141519A0 (en) | 2002-03-10 |
| NO20011312L (no) | 2001-05-16 |
| KR20010099647A (ko) | 2001-11-09 |
| IS5879A (is) | 2001-03-07 |
| ID28785A (id) | 2001-07-05 |
| HUP0103544A3 (en) | 2003-12-29 |
| AR021808A1 (es) | 2002-08-07 |
| NO20011312D0 (no) | 2001-03-15 |
| SE9803156D0 (sv) | 1998-09-16 |
| CZ2001961A3 (cs) | 2001-08-15 |
| ZA200101946B (en) | 2002-06-10 |
| WO2000015218A1 (fr) | 2000-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6169098B1 (en) | Composition and methods employing it for the treatment of 5-HT-mediated disorders | |
| CN103547260B (zh) | 用于治疗中枢系统疾病的包含Brexpiprazole或其盐和第二种药物的组合 | |
| US20110136865A1 (en) | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
| US20050203130A1 (en) | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
| JP4571485B2 (ja) | Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 | |
| EP3400940B1 (fr) | Acomposés ayant une affinité pour le récepteur de la mélatonine en tant qu'agent prophylactique ou thérapeutique du délire | |
| US6472423B1 (en) | Pharmaceutical composition | |
| CA2342341A1 (fr) | Nouvelle composition | |
| AU6378199A (en) | A new composition | |
| CA2342233A1 (fr) | Nouvelle composition | |
| CA2342223A1 (fr) | Nouvelle composition | |
| JP4571645B2 (ja) | Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 | |
| MXPA01002370A (en) | A new composition | |
| MXPA01002543A (en) | A new composition | |
| CA2351674A1 (fr) | Utilisation d'un antagoniste des recepteurs 5ht2a, et 5ht2a/c pour la preparation de medicaments destines au traitement des ronflements et du syndrome de haute resistance des voies aeriennes superieures | |
| AU2004269857A1 (en) | The combination of a serotonin reuptake inhibitor and Amoxapine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |